Regeneron Pharmaceuticals, Inc (REGN) Stock Price

385.94 ▲ +0.37 (+0.10%)
Open: 386.10 Vol: 862.8K Day's range: 382.53 - 386.60 Jan 17, 16:00 EST
IEX Real-Time Price
Free Stock Screener
Loading chart ...
REGN Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY BUY BUY BUY
  5 mins 30 mins Hourly Daily Weekly
MA5 385.82▼ 384.27▲ 384.39▲ 385.76▲ 377.09▲
MA10 385.02▲ 384.24▲ 384.60▲ 382.10▲ 370.87▲
MA20 384.42▲ 384.18▲ 386.78▼ 377.99▲ 334.70▲
MA50 384.44▲ 386.40▼ 384.28▲ 366.11▲ 339.61▲
MA100 384.29▲ 383.97▲ 378.58▲ 329.55▲ 348.27▲
MA200 387.18▼ 378.17▲ 375.70▲ 323.89▲ 375.64▲
  5 mins 30 mins Hourly Daily Weekly
MACD 0.233▲ 0.156▲ -0.375▼ 0.140▲ 6.824▲
RSI 59.895▲ 52.672▲ 51.846▲ 62.559▲ 69.079▲
STOCH 93.912▲ 45.742     50.642     74.975     87.985▲
WILL %R -25.170     -18.687▲ -61.517     -32.937     -10.363▲
CCI 101.079▲ 140.625▲ 103.275▲ 69.864     90.735    
Latest Filters Detected On REGN
▲ MACD $REGN MACD(12,26,9) Crossed Above Signal Line Set Alert
▲ MACD $REGN MACD(12,26,9) Crossed Above Zero Set Alert
RSI $REGN RSI(14) Crossed Above 50 Set Alert
▲ RSI&VOL $REGN RSI Cross Up and Volume Set Alert
Regeneron Pharmaceuticals, Inc News
Regeneron's garetosmab shows benefit in patients with rare bone growth disorder
Thursday, January 09, 2020 04:42 AM
Regeneron Pharmaceuticals (NASDAQ:REGN) announces results from a Phase 2 clinical trial, LUMINA-1, evaluating garetosmab (REGN2477) in patients with fibrodysplasia ossificans progressiva (FOP), a rare ...
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
Thursday, January 09, 2020 03:00 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results from LUMINA-1, a 44-patient, Phase 2, double-blind placebo-controlled trial evaluating garetosmab (REGN2477) in patients with ...
Publication Highlights Regeneron's Costimulatory Bispecific Antibodies, an Emerging Class of Cancer Immunotherapy
Wednesday, January 08, 2020 10:02 AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a publication featured on the cover of Science Translational Medicine describing the potential of a new class of cancer immunotherapy ...
REGN historical stock data
date open high low close volume
17/01/20 386.10 386.60 382.53 385.94 862,800
16/01/20 393.17 394.00 381.82 385.57 620,500
15/01/20 387.42 396.47 387.42 390.75 680,700
14/01/20 378.30 388.42 375.57 387.62 638,900
13/01/20 380.01 380.34 375.13 378.93 637,200
10/01/20 384.62 386.09 380.00 381.41 413,122
09/01/20 383.63 386.54 381.37 383.47 587,500
08/01/20 373.18 384.85 370.71 382.42 743,100
07/01/20 371.56 373.825 368.02 373.13 599,930
06/01/20 368.23 372.14 364.50 371.74 690,800
Quote Details
52wk Low:271.37
52wk High:441.60
Vol:862.8K
Avg Vol(3m):13.7M
1Y Chng:-5.07%
1M Chng:+4.78%
Add to Watch List
More Information
Index NASDAQ 100
Market Cap. 42.33B